Plant-based softgel shell based on gellan gum – a more sustainable ingredient produced by natural fermentation
06/04/22, Pritzwalk (Germany): SIRIO Pharma (SIRIO) – the global nutraceutical contract development and manufacturing organization (CDMO) – will launch its range of next generation plant-based softgels in Europe, including products utilizing its newly created gellan gum technology, at Vitafoods Europe (May 10-12, 2022 in Geneva: booth I40).
The innovation will sit under the company’s Plantegrity TM range – the ‘plant-based softgels with a purpose’ – which in Europe includes SIRIO’s existing carrageenan plant-based softgels and provides greater options for nutraceutical brands.
SIRIO’s next generation gellan gum softgel uses a more sustainable source material and is being launched in response to growing customer demand, but also, as part of the company’s wider efforts, to make nutraceutical production greener, more ethical and environmentally sustainable.
Gellan gum is produced via a natural fermentation process, which means it has a lower environmental impact than other products. A further benefit is that its high concentration of polysaccharides in the shell avoids cross-linking with other ingredients, providing a robust oxygen barrier that ensures freshness of the nutrients.
For more than 15 years SIRIO has been a pioneer in the development of vegetarian softgels and was one of the first CDMOs to launch capsules made of carrageenan derived from algae. SIRIO continued to work on plant-based alternatives, which led to the new, proprietary gellan gum technology. These innovative PlantegrityTM softgels have been extensively tested, maintain a high stability and are ready for market.
“We are doing this not only to meet the needs of environmentally conscious con-sumers, but because we believe in the positive role, we can play in helping to inno-vate so that we can live more sustainably. This new product is just one component of our CSR plan to improve everything from waste materials to power consumption and even the wider impact we have in the local communities we work with.Now customers can choose between two kinds of vegan capsules with and without car-rageenan.” commented Senior Product Manager Kirstin Völz at SIRIO Europe.
The softgels are available to be customized, with clean label options providing consumers ‘plant-based’, ‘gluten-free’, ‘non-GMO’ and ‘sugar-free’ nutraceuticals. The gellan gum can encapsulate both single ingredient and complex formulas – from suspensions (e.g. β-Carotene, Calcium + Vitamin D) to pure oil products (e.g. EPO, CLA, Linseed Oil, Fish Oil, DHA Algal Oil, Vitamin E, Phospholipids, Phosphatidylserine, Vitamin D). Additionally, there is also the flexibility to have fill weights from just 0.15 grams through to 1.3 grams, and the softgels are available inter alia in oval and oblong shapes. All Plantegrity TM softgels are manufactured in compliance with c-GMP, FDA, IFS, BRC and TGA guidelines.
“This naturally-fermented, polysaccharide softgel is a big breakthrough. It has been specifically developed for ethically mission-driven brands, seeking sustainably sourced plant-based softgels,” added Völz.
-ENDS-
About SIRIO
Founded in 1993, SIRIO Pharma Co., Ltd (SIRIO) is the leading global nutraceutical CDMO specialized in developing and manufacturing quality products including softgels, capsules, tablets, powders, gummies, functional beverages, probiotics and other dosage forms. The company has extensive capabilities with multiple manufacturing sites in China, as well as manufacturing facilities in Europe and marketing teams in the USA. SIRIO offers a variety of solutions including product development, manufacturing, packaging and logistics to its customers.
SIRIO is approved by TGA-GMP, NPA/UL GMP, BRC, UL’s Management System 21 CFR Part 111, ISO 9001:2015 certification, and etc. Cooperating with many well-known nutraceutical companies, SIRIO is committed to providing products and service to customers all around the world.
www.siriopharma.com
PR Contacts
De Facto Communications
Alex Heeley or Abdul Khalifeh
Contact: +44 203 735 8165
[email protected] / [email protected]
